1
![Dicerna Pharmaceuticals]()
![Dicerna Pharmaceuticals]()
![Dicerna Pharmaceuticals]()
Dicerna Pharmaceuticals
Leadership team
Jim Jenson (Founder)
Products/ Services
Biotechnology, Genetics, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Lexington, Massachusetts, United States
Established
2007
Company Registration
SEC CIK number: 0001399529
Traded as
NASDAQ:DRNA
Overview
Location
Summary
Dicerna Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative treatments for rare and devastating diseases involving the liver, including rare diseases, chronic liver diseases and cardiovascular diseases involving the liver.
History
Dicerna was founded in 2008 and went public in 2013. The company has established a strong scientific basis in developing applications of its proprietary technology, with a focus on applying RNAi-based therapies to address truly unmet medical needs.
Mission
To become a leader in the development of novel, potential best-in-class therapies for patients suffering from rare and devastating diseases.
Vision
To make a significant difference in the lives of patients for whom current options are inadequate or unavailable.
Key Team
Jim Jenson (Founder)
Recognition and Awards
Dicerna has been granted 12 U.S. patents and has 10 patents pending. The company also has several awards for its technology and contributions to the field of RNAi therapeutics.
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Leadership team
Jim Jenson (Founder)
Products/ Services
Biotechnology, Genetics, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Lexington, Massachusetts, United States
Established
2007
Company Registration
SEC CIK number: 0001399529
Traded as
NASDAQ:DRNA